 Shares of Humanigen skyrocketed as high as 107 to their highest since 2016 on Monday after the biopharmaceutical company revealed that its leading drug candidate met its goal of improving survival among COVID-19 patients without the need for mechanical ventilation in a late-stage trial. The Burlingame, California-company on Monday announced that patients who received lenzilumab, the drug candidate, and other treatments, including steroids and remdesivir, were 54 more likely to survive without the need for mechanical ventilation through day 28, compared with patients receiving placebo and other treatments. 